$CAI News

Wolfe Research Assumes Caris Life Sciences at Peer Perform

Caris Life Sciences Launches Behind the Diagnosis Campaign Spotlighting Patient Lives Transformed by Caris' Comprehensive Genomic Testing

Caris Life Sciences Advances Precision Oncology As Shares Trade Below Targets

Caris Life Sciences Publishes Study on the Caris Lookback Program Demonstrating the Ongoing Clinical Value of Comprehensive Testing with Caris MI Cancer Seek

Caris Life Sciences Announces Publication Of A Caris‑Led Study In The Oncologist The Shows Its Lookback Program's Ability To Identify Previously-Profiled Patients Who Become Eligible For Newly Approved Targeted Therapies

Caris Life Sciences Eyes Bigger Oncology Market After IPO as Revenue Jumps 79%

Caris Life Sciences, Inc. (CAI) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Caris Life Sciences Publishes Study Showing Whole Exome Measurement of Tumor Mutational Burden Results in Increased Overall Survival Compared to Estimates from Targeted Gene Panels

Should Caris’s Q1 Revenue Surge and New AI Cancer Tests Require Action From Caris Life Sciences (CAI) Investors?

Assessing Caris Life Sciences (CAI) Valuation As Shares Trade Below Narrative Fair Value

Caris Life Sciences Submits Application to New York State Department of Health for Caris Assure Blood‑Based Testing Authorization

Citigroup Maintains Buy on Caris Life Sciences, Lowers Price Target to $28

Caris Life Sciences Submits Application To NYSDOH Clinical Laboratory Evaluation Program Seeking Authorization To Perform Caris Assure On Specimens Originating From New York State

JP Morgan Maintains Overweight on Caris Life Sciences, Lowers Price Target to $30

Caris Life Sciences, Inc. (CAI) Q1 2026 Earnings Call Transcript

BTIG Maintains Buy on Caris Life Sciences, Lowers Price Target to $32

Caris Life Sciences (NASDAQ:CAI) Slides 10% Despite Q1 Earnings Beat

Caris (CAI) Q1 2026 Earnings Call Transcript

Caris Life Sciences Q1 Earnings Call Highlights

Caris Life Sciences Reports First Quarter 2026 Financial Results